MARLBOROUGH, Mass., Aug. 22, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced the signing of three new strategic partner agreements in Chile with NovaRed, Vista Group International Ltd (VGL), and GreyMatter. These partnerships mark a significant milestone in Corero's continued expansion and commitment to strengthening its presence in the Latin American market. NovaRed is a leading cybersecurity company ba ...

NEW YORK, Aug. 19, 2024 /PRNewswire/ -- Cohen & Steers, Inc.'s (NYSE: CNS) Board of Directors has appointed Lisa Dolly as a director of the company. Ms. Dolly has also been appointed as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. Ms. Dolly is the former Chief Executive Officer of Pershing LLC, a subsidiary of The Bank of New York Mellon Corporation. Ms. Dolly's career spanned over 30 years at Pershing, including over two decades in seni ...

Plus' CNSide leptomeningeal metastases (LM) FORSEE trial met key primary and secondary endpoints CNSide more than doubled the diagnostic sensitivity vs. gold standard cerebral spinal fluid (CSF) cytology and influenced clinical management decisions in over 90% of LM cases AUSTIN, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for centra ...

Clinical Trial Update - The ReSPECT-LM Phase 1 dose escalation study for Rhenium (186Re) Obisbemeda showed feasibility, safety, and a response in circulating tumor cells (CTCs) in leptomeningeal disease (LM) patients, with a median overall survival of 12 months [1][3] - The trial treated 16 patients across 4 cohorts, with no dose-limiting toxicities observed and the maximum tolerated dose not reached [3] - A mean reduction of 53% in CSF circulating tumor cells (CTCs) was observed at 28 days post-treatment compared to baseline [3] - The mean absorbed radiation dose to the ventricles and cranial subarachnoid space was 156 Gy in Cohort 4, compared to 1 Gy to the spleen [3] FDA Designations - Rhenium (186Re) Obisbemeda received Fast Track designation from the FDA for the treatment of LM [3] - The FDA also granted Orphan Drug designation to Rhenium (186Re) Obisbemeda for the treatment of LM in breast cancer patients [3] Funding and Support - The ReSPECT-LM clinical trial is partially funded by a 3-year, $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) [4][7] - ReSPECT-GBM, another clinical trial evaluating Rhenium (186Re) Obisbemeda, is supported by an award from the National Cancer Institute (NCI) [7] About Leptomeningeal Metastases (LM) - LM is a rare complication of cancer where the primary cancer spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord [5] - Breast cancer is the most common cancer linked to LM, with 3-5% of breast cancer patients developing LM [5] - LM occurs in approximately 5% of cancer patients, with a 1-year survival rate of 7% and a 2-year survival rate of 3% [5] - The incidence of LM is increasing due to longer cancer patient survival and the inability of standard chemotherapies to reach sufficient concentrations in the spinal fluid [6] About Rhenium (186Re) Obisbemeda - Rhenium (186Re) Obisbemeda is a novel injectable radiotherapy designed to deliver targeted high-dose radiation to CNS tumors safely and effectively [7] - Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging [7] About Plus Therapeutics - Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat CNS cancers, including recurrent glioblastoma (GBM) and leptomeningeal metastases (LM) [8] - The company has built a supply chain through strategic partnerships to enable the development, manufacturing, and potential commercialization of its products [8] About CPRIT - The Cancer Prevention & Research Institute of Texas (CPRIT) was established in 2007 and has been awarded an additional $3 billion in 2019, bringing its total investment in cancer research and prevention to $6 billion [9] - CPRIT has awarded over $3 billion in grants to Texas research institutions and organizations, supporting the recruitment of 281 distinguished researchers and the establishment or relocation of 52 companies to Texas [10]

Index Changes - Cohen & Steers announced pending changes to its Global Realty Majors Portfolio Index (GRM) and International Realty Majors Portfolio Index (IRP), effective as of the close of business on August 16, 2024 [1] - Stockland Corporation Ltd (SGP AU) and KDX Realty Investment Corp (8972 JP) will be added to both GRM and IRP indexes [2] - Mirvac Group (MGR AU) and Orix JREIT Inc (8954 JP) will be removed from both GRM and IRP indexes [2] Index Characteristics - GRM and IRP are free-float adjusted, modified market capitalization-weighted total return indexes of selected real estate equity securities [2] - The indexes are quoted intraday on a real-time basis by the Chicago Mercantile Exchange [2] - The modified capitalization-weighted approach and qualitative screening process emphasize companies leading the securitization of real estate globally [2] Index Applications - The indexes can be used as indexing benchmarks, stock selection universes, underlying indexes for derivative instruments, or performance benchmarks [3] - All index weightings are independently calculated by Standard & Poor's [3] Company Overview - Cohen & Steers is a leading global investment manager specializing in real assets and alternative income [3] - The firm manages listed and private real estate, preferred securities, infrastructure, resource equities, commodities, and multi-strategy solutions [3] - Founded in 1986, the company is headquartered in New York City with offices in London, Dublin, Hong Kong, Tokyo, and Singapore [3]

Cohen & Steers, Inc. (CNS) reported preliminary assets under management (AUM) of $84.6 billion as of Jul 31, 2024. This reflected a rise of 4.8% from the prior month's level. The increase was driven by the market appreciation of $41 billion, partially offset by net outflows of $45 million and distributions of $153 million. Cohen & Steers recorded total institutional accounts of $33.8 billion at the end of July 2024, growing 4.8% from the June 2024-end level. Of the total institutional accounts, advisory acc ...

________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | --- | |------------------------------------------------------------------------------ ...

Dividend Announcement - The Board of Directors of Cohen & Steers, Inc declared a cash dividend of $0 59 per share for the third quarter of 2024 [1] - The dividend is payable on August 22, 2024 to stockholders of record as of the close of business on August 12, 2024 [1] Company Overview - Cohen & Steers is a leading global investment manager specializing in real assets and alternative income [2] - The company focuses on listed and private real estate, preferred securities, infrastructure, resource equities, commodities, and multi-strategy solutions [2] - Founded in 1986, the firm is headquartered in New York City with offices in London, Dublin, Hong Kong, Tokyo, and Singapore [2]

Cohen & Steers, Inc. (NYSE:CNS) Q2 2024 Earnings Conference Call July 18, 2024 10:00 AM ET Company Participants Brian Heller - Senior Vice President and Corporate Counsel Matthew Stadler - Executive Vice President Jon Cheigh - Chief Investment Officer Joseph Harvey - Chief Executive Officer and President Conference Call Participants John Dunn - Evercore ISI Adam Beatty - UBS Macrae Sykes - Gabelli Operator Ladies and gentlemen, thank you for standing by. Welcome to the Cohen & Steers' Second Quarter 2024 Ea ...

Anthony Paz - Photographer/iStock via Getty Images Elevator Pitch Cohen & Steers' (NYSE:CNS) shares are awarded a Buy rating. The focus of my earlier May 2, 2024, article was the property market's outlook and CNS' prospects in foreign markets. This latest write-up reviews Cohen & Steers' recently announced Q2 2024 financial results. The company's latest second quarter performance didn't throw up negative surprises as both its top line and bottom line were pretty close to the consensus projections. I have a ...